Stem Cell Therapy for Epidermolysis Bullosa—Does It Work?

Journal of Investigative Dermatology

Volumn 136, Issue 11, 2016, Pages 2119-2121

  Tamai, Katsuto ^a   Uitto, Jouni ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; STROMAL CELL DERIVED FACTOR 1ALPHA;

ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MARROW TRANSPLANTATION; CLINICAL EFFECTIVENESS; CONNECTIVE TISSUE DISEASE; EPIDERMOLYSIS BULLOSA; GENE MUTATION; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NOTE; PRECLINICAL STUDY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; GENE THERAPY; GENETICS; PROCEDURES;

EPIDERMOLYSIS BULLOSA; GENETIC THERAPY; HUMANS; STEM CELL TRANSPLANTATION;

EID: 84994787742     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.07.004     Document Type: Note

References (19)

1. Aikawa, E., Fujita, R., Kikuchi, Y., Kaneda, Y., Tamai, K., Systemic high-mobility group box 1 administration suppresses skin inflammation by inducing an accumulation of PDGFRalpha(+) mesenchymal cells from bone marrow. Sci Rep, 5, 2015, 11008.
2. Chino, T., Tamai, K., Yamazaki, T., Otsuru, S., Kikuchi, Y., Nimura, K., et al. Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 173 (2008), 803–814.
3. Conget, P., Rodriguez, F., Kramer, S., Allers, C., Simon, V., Palisson, F., et al. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 12 (2010), 429–431.
4. Dominici, M., Marino, R., Rasini, V., Spano, C., Paolucci, P., Conte, P., et al. Donor cell-derived osteopoiesis originates from a self-renewing stem cell with a limited regenerative contribution after transplantation. Blood 111 (2008), 4386–4391.
5. El-Darouti, M., Fawzy, M., Amin, I., Abdel Hay, R., Hegazy, R., Gabr, H., et al. Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial. Dermatol Ther 29 (2016), 96–100.
6. Fine, J.D., Bruckner-Tuderman, L., Eady, R.A., Bauer, E.A., Bauer, J.W., Has, C., et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol 70 (2014), 1103–1126.
7. Geyer, M.B., Radhakrishnan, K., Giller, R., Umegaki, N., Harel, S., Kiuru, M., et al. Reduced toxicity conditioning and allogeneic hematopoietic progenitor cell transplantation for recessive dystrophic epidermolysis bullosa. J Pediatr 167 (2015), 765–769.
8. Hammersen, J., Has, C., Naumann-Bartsch, N., Stachel, D., Kiritsi, D., Söder, S., et al. Genotype, clinical course, and therapeutic decision making in 76 infants with severe generalized junctional epidermolysis bullosa. J Invest Dermatol 136 (2016), 2150–2157.
9. Horwitz, E.M., Prockop, D.J., Fitzpatrick, L.A., Koo, W.W., Gordon, P.L., Neel, M., et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5 (1999), 309–313.
10. Horwitz, E.M., Prockop, D.J., Gordon, P.L., Koo, W.W., Fitzpatrick, L.A., Neel, M.D., et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97 (2001), 1227–1231.
11. Iinuma, S., Aikawa, E., Tamai, K., Fujita, R., Kikuchi, Y., Chino, T., et al. Transplanted bone marrow-derived circulating PDGFRalpha+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft. J Immunol 194 (2015), 1996–2003.
12. Perdoni, C., McGrath, J.A., Tolar, J., Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa. Stem Cell Res Ther, 5, 2014, 121.
13. Petrof, G., Lwin, S.M., Martinez-Queipo, M., Abdul-Wahab, A., Tso, S., Mellerio, J.E., et al. Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 135 (2015), 2319–2321.
14. Tamai, K., Yamazaki, T., Chino, T., Ishii, M., Otsuru, S., Kikuchi, Y., et al. PDGFR{alpha}-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci USA 108 (2011), 6609–6614.
15. Tolar, J., Ishida-Yamamoto, A., Riddle, M., McElmurry, R.T., Osborn, M., Xia, L., et al. Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood 113 (2009), 1167–1174.
16. Tolar, J., Wagner, J.E., Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix. Lancet 382 (2013), 1214–1223.
17. Uitto, J., Bruckner-Tuderman, L., Christiano, A.M., McGrath, J.A., Has, C., South, A.P., et al. Progress towards treatment and cure of epidermolysis bullosa: Summary of the DEBRA International Research Symposium EB2015. J Invest Dermatol 136 (2016), 352–358.
18. Wagner, J.E., Ishida-Yamamoto, A., McGrath, J.A., Hordinsky, M., Keene, D.R., Woodley, D.T., et al. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 363 (2010), 629–639.
19. Woodley, D.T., Chen, M., Recessive dystrophic epidermolysis bullosa: advances in the laboratory leading to new therapies. J Invest Dermatol 135 (2015), 1705–1707.